Renhe Yikang Group Co., Ltd.

Primary objective: To study the pharmacokinetics of arginine ibuprofen granules (specification: 0.4g (in terms of ibuprofen), test preparation) held by Renhe Yikang Huize Pharmaceutical Hebei Co., Ltd. in healthy subjects under fasting and postprandial conditions, using arginine ibuprofen granules (trade name: Spodek®; specification: 0.4g (in terms of ibuprofen)) held by Hainan Zanbang Pharmaceutical Co., Ltd. as the reference preparation, and evaluate whether the test preparation and the reference preparation are bioequivalent. Secondary objective: To observe the safety of the test preparation and the reference preparation in healthy subjects.

Main purpose of the test: In healthy subjects, under fasting and postprandial conditions, evocarnet tablets (specification: 2 mg; trade name: Orkedia®) held by Kyowa Coron Co., Ltd. were used as the reference preparation. Study the pharmacokinetics of evocarnet tablets (specification: 2 mg; test preparation) developed by Renhe Yikang Huize Pharmaceutical Hebei Co., Ltd., and evaluate whether the test preparation and the reference preparation are bioequivalent. Secondary test purpose: to observe the safety of the test preparation and reference preparation in healthy subjects.

Primary study objective: In healthy subjects, under postprandial conditions, using indobufen tablets (trade name: IBUSTRIN®; specification: 200 mg) held by Pfizer Italia S.r.l as the reference preparation, to study the pharmacokinetics of indobufen tablets (specification: 0.2 g; test preparation) held by Renhe Yikang Group Co., Ltd., and to evaluate whether the test preparation and the reference preparation are bioequivalent. Secondary study objective: To observe the safety of the test preparation and the reference preparation in healthy subjects.